Added to YB: 2024-04-17
Pitch date: 2024-03-29
HUMA [bullish]
Humacyte, Inc.
-63.14%
current return
Author Info
No bio for this author
Company Info
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Market Cap
$194.9M
Pitch Price
$3.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.33
P/E
-3.91
EV/Sales
144.12
Sector
Biotechnology
Category
growth
Exploring Humacyte's Potential in Regenerative Medicine
HUMA: Off-the-shelf human tissue grafts for vascular surgery. Potential standard of care for hemodialysis (20% mkt) & vascular trauma. Ph3 dialysis data in Q3, prev. trial shows lower infection & better remodeling vs ePTFE. Dialysis in women & PAD next focus. ~$300M mkt cap with funding thru FDA in Aug.
Read full article (7 min)